Alcoholism, a pervasive global health issue, demands innovative and effective treatment modalities. Recent interest in psychedelic drug therapy has opened new possibilities for addressing the complexities of alcohol use disorder (AUD). This research paper provides a comprehensive analysis of the groundbreaking trial conducted by New York University, which investigated the therapeutic potential of psilocybin, a classic psychedelic substance, in treating alcoholism. The trial's methodology included a double-blind randomized clinical trial measuring the efficacy of psilocybin against a placebo.Results indicated that 50% of the patients who received psilocybin stopped drinking altogether. These findings signify the potential of psychedelic drug therapy as a transformative intervention for alcoholism and highlight the need for further research in this promising field.